---
title: Abbott Laboratories (ABT) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/abt
ticker: ABT
as_of: 2026-10-17
sector: Healthcare
industry: Medical - Devices
---
# Abbott Laboratories (ABT)

Abbott Laboratories (ABT) closed at $104.88 on Oct 16, 2026, undervalued by 3% vs its model value of $108.18 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $104.88 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $108.18 |
| Price vs model | undervalued by 3% vs model |
| Range of that model | $70.17 – $245.05 |
| Market value | $181.5B |
| P/E (fiscal 2025) | 28.2 |
| Net margin (fiscal 2025) | 14.7% |
| Free cash flow (fiscal 2025) | $7.4B |
| Dividend yield (trailing twelve months) | 2.40% |
| Beta | 0.58 |
| Cost of capital (WACC) | 7.80% |
| Business classification | Dividend Payer (Low/slowing growth (~5% recent), Moderate margins (15% net margin), Pays dividends, Highly cyclical earnings) |

## Dividends

| Figure | Value |
| --- | ---: |
| Trailing dividend yield | 2.40% |
| Dividends per share, last 12 months | $2.52 |
| Dividends / free cash flow (fiscal 2025) | 55.7% |
| Raised | 12 years in a row |
| Growth over 5 years | 7.0% a year |
| Latest payment | $0.63, ex-date Oct 15, 2026, paid Nov 16, 2026 |

| Year of payments | Dividends per share |
| --- | ---: |
| To Oct 14, 2021 | $1.80 |
| To Oct 13, 2022 | $1.88 |
| To Oct 12, 2023 | $2.04 |
| To Oct 15, 2024 | $2.20 |
| To Oct 15, 2025 | $2.36 |
| Trailing twelve months (to Oct 15, 2026) | $2.52 |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $108.18 | $70.17 | $245.05 |
| DCF · Perpetuity growth · 10y | cross check | $121.90 | $80.37 | $269.63 |
| DCF · EBITDA exit · 5y | cross check | $128.28 | $91.99 | $171.02 |
| DCF · EBITDA exit · 10y | cross check | $139.53 | $98.06 | $194.82 |
| P/E · peers | cross check | $104.82 | $81.97 | $160.68 |
| P/E · own history | cross check | $127.49 | $113.06 | $147.34 |
| PEG | sanity check | $108.39 | $108.39 | $108.39 |
| EV/EBITDA · peers | cross check | $103.45 | $96.67 | $162.88 |
| EV/Revenue · peers | cross check | $138.11 | $91.92 | $188.18 |
| Earnings power value | cross check | $34.53 | $28.55 | $43.35 |
| Dividend discount | cross check | $61.25 | $41.12 | $105.21 |

## Insider activity (SEC Form 4)

Past 90 days: 0 open-market buys ($0) and 4 open-market sales ($46.9M); 10b5-1 plan sales included.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Sep 30, 2026 | Stratton John G | Director | Grant / award | 397 | $39,235.5 |
| Sep 30, 2026 | Gonzalez Patricia Paola | Director | Grant / award | 333 | $32,910.4 |
| Sep 30, 2026 | Conroy Kevin T | Director | Grant / award | 318 | $31,427.9 |
| Sep 30, 2026 | Ahuja Nita | Director | Grant / award | 318 | $31,427.9 |
| Sep 30, 2026 | Roman Michael F | Director | Grant / award | 381 | $37,654.2 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Aug 20, 2026 | 8-K | 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1800/000110465926099247/tm2623675d1_8k.htm |
| Jul 28, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm |
| Jul 16, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1800/000162828026048377/abt-20260716.htm |
| Apr 29, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1800/000162828026028357/abt-20260331.htm |
| Apr 27, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 5.03 Amendment to Articles/Bylaws; 5.07 Submission of Matters to a Shareholder Vote; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1800/000110465926049434/tm2612318d1_8k.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Jensen | 2026-06-30 | 885,262 | $80.3M |
| Mason Hawkins | 2026-06-30 | 840,747 | $76.3M |
| Mairs & Power | 2026-06-30 | 729,358 | $66.2M |
| Bridgewater | 2026-06-30 | 59,775 | $5.4M |

9 tracked managers in all.

## About

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vacci…

---

Source: https://sweetvaluelab.com/stocks/abt (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.